524 related articles for article (PubMed ID: 26593949)
21. Crosstalk of the Androgen Receptor with Transcriptional Collaborators: Potential Therapeutic Targets for Castration-Resistant Prostate Cancer.
Obinata D; Takayama K; Takahashi S; Inoue S
Cancers (Basel); 2017 Feb; 9(3):. PubMed ID: 28264478
[TBL] [Abstract][Full Text] [Related]
22. Serum follicle-stimulating hormone levels predict time to development of castration-resistant prostate cancer.
Hoare D; Skinner TA; Black A; Robert Siemens D
Can Urol Assoc J; 2015; 9(3-4):122-7. PubMed ID: 26085869
[TBL] [Abstract][Full Text] [Related]
23. [ARV-7: A biomarker for the treatment of metastatic castration-resistant prostate cancer].
Chen ZY; Dong Q; Liu LR; Wei Q
Zhonghua Nan Ke Xue; 2019 Feb; 25(2):172-176. PubMed ID: 32216207
[TBL] [Abstract][Full Text] [Related]
24. Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions.
Tucci M; Zichi C; Buttigliero C; Vignani F; Scagliotti GV; Di Maio M
Onco Targets Ther; 2018; 11():7353-7368. PubMed ID: 30425524
[TBL] [Abstract][Full Text] [Related]
25. Immune Modulation in Prostate Cancer Patients Treated with Androgen Receptor (AR)-Targeted Therapy.
Conteduca V; Caffo O; Scarpi E; Sepe P; Galli L; Fratino L; Maines F; Chiuri VE; Santoni M; Zanardi E; Massari F; Toma I; Lolli C; Schepisi G; Sbrana A; Kinspergher S; Cursano MC; Casadei C; Modonesi C; Santini D; Procopio G; De Giorgi U
J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32580478
[TBL] [Abstract][Full Text] [Related]
26. Androgen receptor: what we know and what we expect in castration-resistant prostate cancer.
Cai Z; Chen W; Zhang J; Li H
Int Urol Nephrol; 2018 Oct; 50(10):1753-1764. PubMed ID: 30128923
[TBL] [Abstract][Full Text] [Related]
27. Role of prostate cancer stem-like cells in the development of antiandrogen resistance.
Kushwaha PP; Verma S; Kumar S; Gupta S
Cancer Drug Resist; 2022; 5(2):459-471. PubMed ID: 35800367
[TBL] [Abstract][Full Text] [Related]
28. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
29. Androgen receptor co-regulatory networks in castration-resistant prostate cancer.
Sung YY; Cheung E
Endocr Relat Cancer; 2014 Feb; 21(1):R1-R11. PubMed ID: 24152433
[TBL] [Abstract][Full Text] [Related]
30. Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy.
Pham T; Sadowski MC; Li H; Richard DJ; d'Emden MC; Richard K
Exp Hematol Oncol; 2015; 5():15. PubMed ID: 27340608
[TBL] [Abstract][Full Text] [Related]
31. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
Martin SK; Kyprianou N
Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
[TBL] [Abstract][Full Text] [Related]
32. Novel approach to therapeutic targeting of castration-resistant prostate cancer.
Shankar E; Franco D; Iqbal O; El-Hayek V; Gupta S
Med Hypotheses; 2020 Feb; 140():109639. PubMed ID: 32097843
[TBL] [Abstract][Full Text] [Related]
33. Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance.
Crona DJ; Whang YE
Cancers (Basel); 2017 Jun; 9(6):. PubMed ID: 28604629
[TBL] [Abstract][Full Text] [Related]
34. Castration-Resistant Prostate Cancer: From Uncovered Resistance Mechanisms to Current Treatments.
Le TK; Duong QH; Baylot V; Fargette C; Baboudjian M; Colleaux L; Taïeb D; Rocchi P
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894414
[TBL] [Abstract][Full Text] [Related]
35. [Predictive factor analysis of time to progression of castration-resistant prostate cancer after androgen deprivation therapy].
Ji GJ; Huang C; Song G; Li XS; Song Y; Zhou LQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Aug; 49(4):657-662. PubMed ID: 28816284
[TBL] [Abstract][Full Text] [Related]
36. Androgen receptor signaling and spatial chromatin organization in castration-resistant prostate cancer.
Zhou T; Feng Q
Front Med (Lausanne); 2022; 9():924087. PubMed ID: 35966880
[TBL] [Abstract][Full Text] [Related]
37. Genomic Resistance Patterns to Second-Generation Androgen Blockade in Paired Tumor Biopsies of Metastatic Castration-Resistant Prostate Cancer.
Han GC; Hwang J; Wankowicz SAM; Zhang Z; Liu D; Cibulskis C; Gaviola GC; Ghazikhanian V; McKay RR; Bubley GJ; Carter SL; Balk SP; Hahn WC; Taplin ME; Van Allen EM
JCO Precis Oncol; 2017; 1():. PubMed ID: 32913968
[TBL] [Abstract][Full Text] [Related]
38. Resistance to second generation antiandrogens in prostate cancer: pathways and mechanisms.
Verma S; Prajapati KS; Kushwaha PP; Shuaib M; Kumar Singh A; Kumar S; Gupta S
Cancer Drug Resist; 2020; 3(4):742-761. PubMed ID: 35582225
[TBL] [Abstract][Full Text] [Related]
39. [Castration resistance mechanisms in prostate cancer.].
Martínez-Breijo S; Chantada-Abal V; Aller-Rodríguez M; Bohórquez-Cruz M; Sacristán-Lista F; Ponce-Díaz J; Vázquez-Martul D; Lamas-Díaz L
Arch Esp Urol; 2018 Sep; 71(8):628-638. PubMed ID: 30319123
[TBL] [Abstract][Full Text] [Related]
40. The Efflux Transporter ABCG2 Maintains Prostate Stem Cells.
Sabnis NG; Miller A; Titus MA; Huss WJ
Mol Cancer Res; 2017 Feb; 15(2):128-140. PubMed ID: 27856956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
